Dr. Margaret von Mehren Appointed New Vice Chair of the Department of Hematology/Oncology at Fox Chase Cancer Center

Dr. von Mehren, chief of the Division of Sarcoma Medical Oncology and lead author of the study
Dr. von Mehren, appointed vice chair of the Department of Hematology/Oncology

PHILADELPHIA (January 31, 2022)—Margaret von Mehren, MD, chief of the Division of Sarcoma Medical Oncology at Fox Chase Cancer Center, was recently appointed the new vice chair of the Department of Hematology/Oncology.

“It is an honor to serve the Department of Hematology and Oncology, which I have been a member of since 1993 when I started my fellowship; I never anticipated this when I joined,” said von Mehren. “It is my privilege to work with and for our talented and committed faculty in the department.”

In addition to her new position, von Mehren is also the associate director for clinical research, physician director of the Clinical Trials Office, and a member of the Cancer Epigenetics Institute at Fox Chase. In addition, she holds a number of positions with the National Comprehensive Cancer Network, including being an adolescent and young adult oncology panel member, editorial board member for their journal (JNCCN), and soft tissue sarcoma panel member.

Her specialties include gastrointestinal stromal tumors, melanoma, sarcoma, skin cancer, and uterine sarcoma. She has also been named one of Philadelphia Magazine’s Top Doctors from 2006 through 2021.

“Dr. von Mehren and I have worked together for almost five years. She exemplifies ‘quiet competence,’ that is to say, evaluating problems, proposing solutions, and getting results without drama,” said Martin J. Edelman, MD, chair of the Department of Hematology/Oncology. “I look forward to working with her in this new role as we continue to grow and expand the department.”

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427